Menu
Search
|

Menu

Close
X

PDL BioPharma Inc PDLI.OQ (NASDAQ Stock Exchange Global Select Market)

2.54 USD
-0.02 (-0.78%)
As of Oct 19
chart
Previous Close 2.56
Open 2.55
Volume 242,175
3m Avg Volume 383,413
Today’s High 2.63
Today’s Low 2.52
52 Week High 3.55
52 Week Low 2.25
Shares Outstanding (mil) 145.40
Market Capitalization (mil) 383.86
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
3.00 Mean rating from 1 analysts

KEY STATS

Revenue (mm, USD)
FY18
85
FY17
320
FY16
244
FY15
590
EPS (USD)
FY18
-0.754
FY17
0.718
FY16
0.388
FY15
2.007
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.14
Price to Sales (TTM)
vs sector
1.78
6.55
Price to Book (MRQ)
vs sector
0.54
4.00
Price to Cash Flow (TTM)
vs sector
--
21.51
Total Debt to Equity (MRQ)
vs sector
16.97
14.15
LT Debt to Equity (MRQ)
vs sector
16.97
11.31
Return on Investment (TTM)
vs sector
-6.95
12.83
Return on Equity (TTM)
vs sector
-8.74
14.95

EXECUTIVE LEADERSHIP

Dominique Monnet
President, Since 2017
Salary: $155,303.00
Bonus: --
John McLaughlin
Chief Executive Officer, Director, Since 2017
Salary: $717,003.00
Bonus: --
Peter Garcia
Chief Financial Officer, Vice President, Since 2013
Salary: $430,301.00
Bonus: --
Christopher Stone
Vice President, General Counsel, Secretary, Since 2009
Salary: $460,350.00
Bonus: --
Harold Selick
Lead Independent Director, Since 2016
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

932 Southwood Blvd
INCLINE VILLAGE   NV   89451

Phone: +1775.8328500
Site: www.pdl.com

PDL BioPharma, Inc. seeks to provide return for its shareholders by acquiring and managing a portfolio of companies, products, royalty agreements and debt facilities in the biotechnology, pharmaceutical and medical device industries. The Company's segments include income generating assets and product sales. The income generating assets segment consists of royalties from issued patents in the United States and elsewhere, covering the humanization of antibodies, which it refers to as the Queen et al. patents; notes and other long-term receivables, royalty rights-at fair value and equity investments. The Company's product sales segment consists of revenue derived from Tekturna, Tekturna HCT, Rasilez and Rasilez HCT (collectively, the Noden Products or Tekturna) sales. It is focused on the acquisition of additional products. As of December 31, 2016, it had a total of five notes receivable transactions outstanding and one note/royalty (hybrid) receivable transaction outstanding.

SPONSORED STORIES